Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androgen Effects on Reproductive Neuroendocrine Axis in Transgender Men
NCT04321551Phase 4Withdrawn
- Sponsor
- University of California, San Diego
- Start
- Jul 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of testosterone cypionate in gender dysphoria (GD) (2 arms), sponsored by University of California, San Diego. Primary endpoint: Evidence of Luteal Activity at 32 weeks. Planned start Jul 2023; status: withdrawn.
02
Drugs
testosterone cypionate
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NCT04321551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321551.